Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas

doi:10.1155/2021/6696015

科研成果详情

题名	Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
作者	Wu, Zerui1; Xu, Yunqiu 1; Xu, Jiadong 2; Lu, Jianglong1; Cai, Lin1; Li, Qun1; Wang, Chengde1; Su, Zhipeng1
发表日期	2021-06-16
发表期刊	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Cell death Cell proliferation Mammals Antitumor effect Cancer cells Clinical effectiveness Drug resistance Inhibition of tumor growth Pituitary adenoma Signaling pathways Tumor growth
其他关键词	SIGNALING PATHWAYS ; CELL-DEATH ; ACTIVATION ; MTOR ; SUPPRESSION ; METABOLISM ; AUTOPHAGY ; INDUCTION ; COMPLEX ; CANCER
摘要	Cabergoline (CAB) is the first choice for treatment of prolactinoma and the most common subtype of pituitary adenoma. However, drug resistance and lack of effectiveness in other pituitary tumor types remain clinical challenges to this treatment. Brusatol (BT) is known to inhibit cell growth and promote apoptosis in a variety of cancer cells. In our present studies, we investigate the effects of BT on pituitary tumor cell proliferation in vitro and in vivo. BT treatment resulted in an increase in Annexin V-expressing cells and promoted the expression of apoptosis-related proteins in rat and human pituitary tumor cells. Investigation of the mechanism underlying this effect revealed that BT increased the production of reactive oxygen species (ROS) and inhibited the phosphorylation of 4EBP1 and S6K1. Furthermore, treatment with a combination of BT and CAB resulted in greater antitumor effects than either treatment alone in nude mice and pituitary tumor cells. Collectively, our results suggest that the BT-induced ROS accumulation and inhibition of mTORC1 signaling pathway leads to inhibition of tumor growth. Combined use of CAB and BT may increase the clinical effectiveness of treatment for human pituitary adenomas.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81801367]; Wenzhou Science and Technology Project [Y20180152]; Medical Health Science and Technology Research Project of Zhejiang Province of China [2020RC079]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LY19C070002]
出版者	HINDAWI LTD
出版地	LONDON
ISSN	1942-0900
EISSN	1942-0994
卷号	2021 页码:6696015
DOI	10.1155/2021/6696015
页数	38
WOS类目	Cell Biology
WOS研究方向	Cell Biology
WOS记录号	WOS:000670559900001
收录类别	SCIE ; PUBMED ; EI ; SCOPUS
EI入藏号	20212710589187
EI主题词	Tumors
URL	查看原文
PubMed ID	34221237
PMC记录号	PMC8221873
SCOPUSEID	2-s2.0-85109039729
通讯作者地址	[Wang, Chengde]Department of Neurosurgery,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China ; [Su, Zhipeng]Department of Neurosurgery,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Biochemistry;Aging;Cell Biology
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/18945
专题	附属第一医院_神经外科其他_附属舟山医院（舟山医院）
通讯作者	Wang, Chengde; Su, Zhipeng
作者单位	1.Department of Neurosurgery,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China; 2.Department of Cardiothoracic Surgery,Zhoushan Hospital,Wenzhou Medical University,Zhoushan,316000,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Wu, Zerui,Xu, Yunqiu,Xu, Jiadong,et al. Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas[J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY,2021,2021:6696015.
APA	Wu, Zerui., Xu, Yunqiu., Xu, Jiadong., Lu, Jianglong., Cai, Lin., ... & Su, Zhipeng. (2021). Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 6696015.
MLA	Wu, Zerui,et al."Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas".OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021(2021):6696015.